Rituximab in IgA Nephropathy
Standard kidney-protection therapy remains the best available option for IgA nephropathy, as adding rituximab didn't improve outcomes in this major trial.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Comparative efficacy and safety of first-line therapies for advanced…
Anti-PD-1 immunotherapy combined with chemotherapy shows the strongest evidence as a first-line treatment for advanced gastric cancers lacking HER2.
Standard additionWeakly supervised deep learning predicts perineural invasion from H&E…
AI can help pathologists spot nerve invasion in tongue cancer from tissue slides, potentially flagging important findings that might otherwise be missed.
Standard additionImpact of venetoclax-based therapies on CLL-associated autoimmune cytopenias
Venetoclax-based therapy shows promise for managing autoimmune blood cell deficiencies that sometimes occur with chronic lymphocytic leukemia.
Standard additionFirst-line systemic treatment patterns and outcomes in lung cancer…
Adding bevacizumab to chemotherapy improved survival in lung cancer patients with fluid around the lungs who lacked genetic driver mutations.